GMO examines why value investing has lagged for over a decade, arguing the weakness reflects multiple cyclical pressures rather than a structural breakdown. Value stocks have trailed in 9 of the past 12 years, yet widening valuation discounts suggest potential reversal as several headwinds normalize.
Value Investing: Bruised by 1000 Cuts
GMO
Rick Friedman
Research
4 Pages
Key Takeaways
Persistent Underperformance Trend: Value stocks lagged the market in 9 of 12 years, underperforming by roughly 2.0% annually during the most recent cycle.
Diminished Income Advantage: Value’s historical yield edge shrank, with dividends and buybacks contributing about 0.8% less relative return versus long-term norms.
Weaker Rebalancing Tailwinds: Rebalancing benefits declined from 2.2% historically to 1.3%, reducing a key structural driver of value outperformance.